The abstract is read at the publisher; the summary is JClub's.
Neoadjuvant serplulimab plus SOX followed by adjuvant serplulimab significantly improves event-free survival versus perioperative SOX in PD-L1 CPS ≥10 resectable gastric or gastro-oesophageal junction adenocarcinoma (HR 0·65).
- Why it matters: Perioperative chemo-immunotherapy outcomes vary in resectable gastric or gastro-oesophageal junction adenocarcinoma, and PD-L1-positive patients need more reliable efficacy and safety evidence.
- What they did: In ASTRUM-006, a randomised, double-blind phase 3 trial across 75 hospitals in China and Thailand, 588 PD-L1-positive patients (CPS ≥5) received neoadjuvant serplulimab (4·5 mg/kg) or placebo with SOX, then adjuvant serplulimab or SOX.
- The result: Median event-free survival was NR vs 42·0 months in PD-L1 CPS ≥10 (p=0·0082) and NR vs 35·9 months in the intention-to-treat population (p=0·015); grade ≥3 treatment-related adverse events were 47% vs 59%.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.